3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
48
Lymphoma, Large B-Cell, Diffuse
36
Multiple Myeloma
33
Burkitt Lymphoma
32
Lymphoma
30
Leukemia, Myeloid, Acute
29
Lymphoma, Non-Hodgkin
28
Recurrence
26
Breast Neoplasms
26
Lymphoma, B-Cell
23
Neoplasms
22
Myelodysplastic Syndromes
20
Lymphoma, Follicular
20
Leukemia, Lymphocytic, Chronic, B-Cell
20
Hodgkin Disease
17
Triple Negative Breast Neoplasms
16
Leukemia
16
Ovarian Neoplasms
15
Hematologic Neoplasms
15
Melanoma
14
Neuroblastoma
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
12
Lymphoma, Mantle-Cell
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Pancreatic Neoplasms
11
Leukemia, Biphenotypic, Acute
10
Sarcoma
9
Neoplasm Metastasis
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia, Myelomonocytic, Chronic
9
Interventions
belantamab mafodotin
2
Dexamethasone
1
Cyclophosphamide
1
Bortezomib
1
Antineoplastic Protocols
1
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Amyloidosis
×
Cyclophosphamide
×
90 days
×
Clear all
NCT07224672
2026-03-17
ALANIS
GlaxoSmithKline
Phase 2
Not yet recruiting
60 enrolled